X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

PhRMA submits comments to USPTO highlighting important role of patent system in medicine development

By Megan Van Etten  |    February 23, 2023
PhRMA responded to the U.S. Patent and Trademark Office’s (USPTO) request for comments regarding USPTO initiatives to ensure the robustness and reliability of patent rights.   Read More

Six ways I-MAK is lying about biopharma patents

By Megan Van Etten  |    November 16, 2022
The Arnold-Venture funded advocacy group Initiative for Medicines, Access & Knowledge, Inc. (or I-MAK) is on a global media tour, espousing their point of view on the patent system. Some experts and...   Read More

New report ignores benefits of patent system to innovation and patients

By Megan Van Etten  |    September 30, 2022
A recent report from the Initiative for Medicines, Access & Knowledge – known as I-MAK – highlights fundamental misunderstandings about America’s patent system and how it benefits patients and...   Read More

The dangers of expanding the TRIPS waiver

By Megan Van Etten  |    September 19, 2022
World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful...   Read More

Patent policy changes proposed by USPTO and FDA would leave patients behind

By Megan Van Etten  |    July 22, 2022
Kathi Vidal, Director of the USPTO, and Robert M. Califf, FDA Commissioner, recently outlined several policy areas where they plan to collaborate on addressing drug pricing. PhRMA supports the goal...   Read More

The time is now to address Brazil’s notorious patent backlog

By Anjam Aziz  |    May 20, 2022
It has been widely acknowledged that long patent examination delays cripple innovation, hinder economies, impede job creation and frustrate the launch of new products. Increased patent review times...   Read More

Legislation threatens patent protections and future innovation

By Tom Wilbur  |    January 12, 2022
Recently introduced legislation, the “Restoring the America Invents Act (RAIA),” if enacted, would push the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office to grant more...   Read More

Patients and innovators lose if the government pursues ‘march-in’

By Megan Van Etten  |    September 7, 2021
The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...   Read More

IP Explained: How does the U.S. patent process work?

By Megan Van Etten  |    June 24, 2021
Have you ever used a Teflon-coated pan or hit a golf ball down the fairway? Had a friend or family member receive treatment with a new medication? All these products were developed because patents...   Read More

New polling shows Americans are sounding the alarm on the TRIPS IP waiver

By Cynthia Hicks  |    May 14, 2021
Last week, the Biden administration announced support for a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which could lead to...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates